School of Medicine, Southeast University, Nanjing, China.
Department of Gastroenterology, Zhongda Hospital of Southeast University, HuNan Street, GuLou District, Nanjing, China.
Dig Dis Sci. 2024 Nov;69(11):4187-4202. doi: 10.1007/s10620-024-08597-1. Epub 2024 Sep 25.
Crohn's disease (CD) have an increased risk of gallstone disease. We aimed to systematically evaluate the prevalence rate and relevant risk factors of gallstones in CD patients.
A comprehensive search of PubMed, Embase, and Web of Science databases from inception to September 10, 2023, identified studies investigating risk factors for gallstone development among CD patients. Gender, age, body mass index, disease duration, disease site, stenosis, prior surgery, hospitalization times, corticosteroids, immunomodulators, and total parenteral nutrition (TPN) were assessed as potential risk factors. Odds ratios (OR) and confidence intervals (CI) were calculated.
Among 1184 articles, 11 observational studies (3588 patients) were included. The prevalence of CD patients with gallstones was approximately 14.7%. Factors significantly associated with increased gallstone risk included Age ≥ 40 years old (OR 3.06, 95% CI 2.09- 4.48), disease duration > 15 years (OR 3.01, 95% CI 2.06-4.42), lifetime surgery(OR 2.50, 95% CI 1.99-3.12), disease located in ileocolon (OR 1.38, 95% CI 1.04-1.83) and ileocecal(OR 1.93, 95% CI 1.16-3.21), multiple hospitalizations(OR 4.26, 95% CI 2.43-7.46), corticosteroid treatments(OR 2.65, 95% CI 1.52-4.63), immunomodulator therapy(OR 1.94, 95% CI 1.12-3.38), and TPN use(OR 2.66, 95% CI 1.29-5.51). Sex, stenosis, overweight, or low weight did not significantly increase the risk of gallstone developing.
Age, long disease duration, specific disease locations (ileocolon, ileocecal), surgery, number of hospitalizations, corticosteroids, immunomodulator therapy, and TPN were identified as factors that increased the risk of gallstones in CD patients. About 14.7% of CD patients experience gallstones, so raising awareness and implementing prevention are needed.
PROSPERO (CRD42023449299).
克罗恩病(CD)患者发生胆石病的风险增加。本研究旨在系统评估 CD 患者胆石症的患病率和相关危险因素。
全面检索 PubMed、Embase 和 Web of Science 数据库,从建库至 2023 年 9 月 10 日,以评估 CD 患者胆石形成的相关危险因素。性别、年龄、体重指数、疾病病程、病变部位、狭窄、既往手术、住院次数、皮质类固醇、免疫调节剂和全胃肠外营养(TPN)被评估为潜在的危险因素。计算比值比(OR)和置信区间(CI)。
在 1184 篇文章中,有 11 项观察性研究(3588 例患者)被纳入。约 14.7%的 CD 患者有胆石症。与胆石症风险增加显著相关的因素包括年龄≥40 岁(OR 3.06,95%CI 2.09-4.48)、疾病病程>15 年(OR 3.01,95%CI 2.06-4.42)、终生手术(OR 2.50,95%CI 1.99-3.12)、病变位于回结肠(OR 1.38,95%CI 1.04-1.83)和回盲部(OR 1.93,95%CI 1.16-3.21)、多次住院(OR 4.26,95%CI 2.43-7.46)、皮质类固醇治疗(OR 2.65,95%CI 1.52-4.63)、免疫调节剂治疗(OR 1.94,95%CI 1.12-3.38)和 TPN 应用(OR 2.66,95%CI 1.29-5.51)。性别、狭窄、超重或体重过低并不显著增加胆石形成的风险。
年龄、长病程、特定病变部位(回结肠、回盲部)、手术、住院次数、皮质类固醇、免疫调节剂治疗和 TPN 是 CD 患者胆石形成风险增加的因素。约 14.7%的 CD 患者发生胆石症,因此需要提高认识并进行预防。
PROSPERO(CRD42023449299)。